Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structures of engineered Clostridium botulinum neurotoxin derivatives.

Acta crystallographica. Section F, Structural biology and crystallization communications - 1 Dec 2011

Masuyer Geoffrey, Stancombe Patrick, Chaddock John A, Acharya K Ravi

Abstract excerpt

Targeted secretion inhibitors (TSIs) are a new class of engineered biopharmaceutical molecules derived from the botulinum neurotoxins (BoNTs). They consist of the metalloprotease light chain (LC) and translocation domain (Hn) of BoNT; they thus lack the native toxicity towards motor neurons but are able to target soluble N-ethylmaleimide-sensitive fusion protein attachment receptor (SNARE) proteins. These...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Botulinum Toxins
Share to Models, Molecular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Engineering

Share to Protein Structure, Quaternary

Share to Protein Structure, Tertiary

Source

Open in PubMed Open full text

Identifiers

PMID: 22139146
DOI: 10.1107/S1744309111034671
PMCID: PMC3232119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structures of engineered Clostridium botulinum neurotoxin derivatives.PMID 22139146Read ↗

Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodiesSemantic proximity Read ↗

A Comprehensive Structural Analysis of Clostridium botulinum Neurotoxin A Cell-Binding Domain from Different SubtypesSemantic proximity Read ↗

Light Chain Diversity among the Botulinum NeurotoxinsSemantic proximity Read ↗

The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A SubtypesSemantic proximity Read ↗

Rational design of botulinum neurotoxin A1 mutants with improved oxidative stability.Semantic proximity Read ↗

Two VHH Antibodies Neutralize Botulinum Neurotoxin E1 by Blocking Its Membrane Translocation in Host Cells.Semantic proximity Read ↗

New Engineered-Chimeric Botulinum Neurotoxin Mutant Acts as an Effective Bivalent Vaccine Against Botulinum Neurotoxin Serotype A and E.Semantic proximity Read ↗

2.3 Å Crystal Structure of Tetanus Neurotoxin Light Chain<sup>,</sup>Semantic proximity Read ↗

Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum NeurotoxinsSemantic proximity Read ↗

Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy.Semantic proximity Read ↗

Substrate recognition strategy for botulinum neurotoxin serotype A.Semantic proximity Read ↗

Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic ApplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.